Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Atherosclerosis Plus
|
April 15, 2024
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial
Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
Journal of Clinical Lipidology
|
January 21, 2026
Different response of plaque regression following achievement of LDL-C <1.8 mmol/L in obese and non-obese patients with diabetes and coronary artery disease: OPTIMAL sub-analysis
Anthony Salib, Yu Kataoka, Stephen J Nicholls, et al.
Journal of Diabetes and Its Complications
|
September 23, 2023
The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial
Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
Atherosclerosis
|
August 16, 2025
Apolipoprotein CIII in statin-treated type 2 diabetic patients: Its implications for plaque progression and instability: The pre-specified analysis from the OPTIMAL randomized controlled trial
Satoshi Kitahara, Yu Kataoka, Stephen J Nicholls, et al.
Atherosclerosis
|
May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and Management
Florian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Atherosclerosis Plus
|
April 15, 2024
Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial
Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
Journal of Clinical Lipidology
|
January 21, 2026
Different response of plaque regression following achievement of LDL-C <1.8 mmol/L in obese and non-obese patients with diabetes and coronary artery disease: OPTIMAL sub-analysis
Anthony Salib, Yu Kataoka, Stephen J Nicholls, et al.
Journal of Diabetes and Its Complications
|
September 23, 2023
The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial
Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, et al.
Atherosclerosis
|
August 16, 2025
Apolipoprotein CIII in statin-treated type 2 diabetic patients: Its implications for plaque progression and instability: The pre-specified analysis from the OPTIMAL randomized controlled trial
Satoshi Kitahara, Yu Kataoka, Stephen J Nicholls, et al.
Atherosclerosis
|
May 8, 2025
The Brussels International Declaration on Lipoprotein(a) Testing and Management
Florian Kronenberg, Nicola Bedlington, Zanfina Ademi, et al.
Page
of 3